30 institutions hold shares in Mereo BioPharma Group plc (MREO), with 517.26k shares held by insiders accounting for 0.77% while institutional investors hold 21.79% of the company’s shares. The shares outstanding are 23.74M, and float is at 14.29M with Short Float at 33.56%. Institutions hold 21.62% of the Float.
The top institutional shareholder in the company is Orbimed Advisors LLC. with over 13.82 million shares valued at $49.46 million. The investor’s holdings represent 13.42% of the MREO Shares outstanding. As of Dec 30, 2020, the second largest holder is Boxer Capital, LLC with 6.23 million shares valued at $22.29 million to account for 6.05% of the shares outstanding. The other top investors are Baker Brothers Advisors, LLC which holds 6.03 million shares representing 5.86% and valued at over $21.59 million, while Vivo Capital, LLC holds 4.10% of the shares totaling 4.22 million with a market value of $15.11 million.
Mereo BioPharma Group plc (NASDAQ: MREO) is -7.54% lower on its value in year-to-date trading and has touched a low of $0.71 and a high of $4.71 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MREO stock was last observed hovering at around $3.59 in the last trading session, with the day’s loss setting it -0.28% off its average median price target of $8.00 for the next 12 months. It is also 58.62% off the consensus price target high of $8.00 offered by 1 analysts, but current levels are 58.62% higher than the price target low of $8.00 for the same period.
Currently trading at $3.31, the stock is -16.21% and -7.00% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.79 million and changing -7.80% at the moment leaves the stock 11.30% off its SMA200. MREO registered 237.76% gain for a year compared to 6-month gain of 26.34%. The firm has a 50-day simple moving average (SMA 50) of $3.8441 and a 200-day simple moving average (SMA200) of $2.9800.
The stock witnessed a -14.91% loss in the last 1 month and extending the period to 3 months gives it a -7.28%, and is -20.05% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.51% over the week and 10.19% over the month.
Distance from 52-week low is 366.20% and -29.74% from its 52-week high.
Mereo BioPharma Group plc (MREO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Mereo BioPharma Group plc (MREO) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 1.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Mereo BioPharma Group plc quarterly earnings per share for the current quarter are estimated at $0..